Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.

Date publication

mai 2025

Journal

Journal for immunotherapy of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe , Dr TRICARD Thibault

Tous les auteurs :
Blanc J, Carnot A, Barthélémy P, Casert V, Sautois B, Van den Brande J, Vanhaudenarde V, Staudacher L, Seront E, Debien V, Ameye L, Kotecki N, Rothé F, Rorive S, Fantoni JC, Tricard T, Roumeguère T, Awada A, Martinez Chanza N

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40413024

Résumé

Immunotherapy is becoming a standard of care for non-metastatic muscle-invasive bladder cancer (MIBC). The optimal chemotherapy partner for chemo-immunotherapy combinations remains unknown. We evaluated the efficacy and safety of neoadjuvant avelumab-based regimens in patients with MIBC.

Mots clés

Bladder Cancer, Genitourinary Cancer, Immune Checkpoint Inhibitor, Neoadjuvant

Référence

J Immunother Cancer. 2025 05 24;13(5):